Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmRubVac: Rubella Immunity and Postpartum Vaccination Response
NCT02934295Completed
- Sponsor
- Hôpital Foch
- Start
- Feb 2012
- Primary completion
- May 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of rubella vaccine, live in rubella, sponsored by Hôpital Foch. Primary endpoint: Anti-Rubella Antibody, E1 at 8 months. Started Feb 2012; status: completed.
02
Drugs
rubella vaccine, live
03
Conditions
rubella
Beyond the preview
Go deeper on NCT02934295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934295.